# Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

Study · id `cardio:ct-nct01546532` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01546532](<https://clinicaltrials.gov/study/NCT01546532>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01546532

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

## Technical summary

Registry record NCT01546532. Randomized; quadruple masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2012-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 118 participants (enrolled count; ClinicalTrials.gov record NCT01546532, source copy `cardio:ctgov-nct01546532-2020-12-19`, retrieved 2026-10-26)
- Start date: 2012-02 (registry gives no type) (ClinicalTrials.gov record NCT01546532, source copy `cardio:ctgov-nct01546532-2020-12-19`, retrieved 2026-10-26)
- Primary completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01546532, source copy `cardio:ctgov-nct01546532-2020-12-19`, retrieved 2026-10-26)
- Completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01546532, source copy `cardio:ctgov-nct01546532-2020-12-19`, retrieved 2026-10-26)
- Countries: United States; Germany; Netherlands; Poland (ClinicalTrials.gov record NCT01546532, source copy `cardio:ctgov-nct01546532-2020-12-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01546532-2020-12-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
- Condition: Chronic Heart Failure (CHF)
- Intervention (Drug): RLX030
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study (`cardio:pubmed-25286914`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e1c18fe7f29934b44741ec5a39f5d267a4e15f2f5e14cbb3de902af2486f5622
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
